Leveraging Serosurveillance and Postmortem Surveillance to Quantify the Impact of Coronavirus Disease 2019 in Africa
Open Access
- 5 October 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (3) , 424-432
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has had a devastating impact on global health, the magnitude of which appears to differ intercontinentally: For example, reports suggest that 271 900 per million people have been infected in Europe versus 8800 per million people in Africa. While Africa is the second-largest continent by population, its reported COVID-19 cases comprise <3% of global cases. Although social and environmental explanations have been proposed to clarify this discrepancy, systematic underascertainment of infections may be equally responsible. Methods: We sought to quantify magnitudes of underascertainment in COVID-19's cumulative incidence in Africa. Using serosurveillance and postmortem surveillance, we constructed multiplicative factors estimating ratios of true infections to reported cases in Africa since March 2020. Results: Multiplicative factors derived from serology data (subset of 12 nations) suggested a range of COVID-19 reporting rates, from 1 in 2 infections reported in Cape Verde (July 2020) to 1 in 3795 infections reported in Malawi (June 2020). A similar set of multiplicative factors for all nations derived from postmortem data points toward the same conclusion: Reported COVID-19 cases are unrepresentative of true infections, suggesting that a key reason for low case burden in many African nations is significant underdetection and underreporting. Conclusions: While estimating the exact burden of COVID-19 is challenging, the multiplicative factors we present furnish incidence estimates reflecting likely-to-worst-case ranges of infection. Our results stress the need for expansive surveillance to allocate resources in areas experiencing discrepancies between reported cases, projected infections, and deaths.Keywords
All Related Versions
Funding Information
- institutional research funds from Pfizer Inc
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (R01GM130668, 2T32AI007535)
- National Institute of General Medical Sciences
- Harvard T. H. Chan School of Public Health
This publication has 24 references indexed in Scilit:
- SeroTracker: a global SARS-CoV-2 seroprevalence dashboardThe Lancet Infectious Diseases, 2021
- An early warning approach to monitor COVID-19 activity with multiple digital traces in near real timeScience Advances, 2021
- Covid-19 deaths in Africa: prospective systematic postmortem surveillance studyBMJ, 2021
- Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomesScientific Reports, 2021
- COVID-19 in the Middle East and North Africa region: an urgent call for reliable, disaggregated and openly shared dataBMJ Global Health, 2021
- Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence SurveysJAMA Network Open, 2021
- Behavioral dynamics of COVID‐19: estimating underreporting, multiple waves, and adherence fatigue across 92 nationsSystem Dynamics Review, 2021
- COVID-19: Unpacking the low number of cases in AfricaPublic Health in Practice, 2020
- Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19Journal of Clinical Virology, 2020
- Identifying Future Disease Hot Spots: Infectious Disease Vulnerability Index2016